O aumento do reflexo de sobressalto na presença de um estímulo que tenha sido previamente pareado a choques nas patas é tomado como índice de medo e nomeado sobressalto potencializado pelo medo (SPM). O congelamento, interrupção de todos os movimentos observáveis, exceto aqueles associados com a respiração, também tem sido utilizado como índice de medo em ratos. Um crescente número de evidências sugere o envolvimento de mecanismos dopaminérgicos em diferentes aspectos da memória afetiva, como sua formação, evocação e expressão. No entanto, resultados sobre como e por meio de quais receptores os mecanismos dopaminérgicos influenciam o medo têm sido inconsistentes. O presente estudo examina o envolvimento dos receptores dopaminérgicos na aquisição e na expressão do medo condicionado à luz. Para isso, foram analisados os efeitos do antagonista D1, SCH 23390, do agonista D1, SKF 38393, do antagonista D2, sulpirida, e do agonista D2, quimpirole, no SPM e no congelamento. A atividade motora dos animais também foi avaliada no teste do campo aberto. SCH 23390, SKF 38393, sulpirida e quimpirole, administrados antes do condicionamento, não produziram efeitos no SPM, mas SCH 23390 diminuiu o congelamento. As administrações de SCH 23390, SKF 38393 e sulpirida antes do teste também não produziram efeitos no SPM e no congelamento. Quimpirole, em doses que agem em receptores pré-sinápticos, causou uma redução significativa no SPM e no congelamento, quando administrado antes do teste. A ação das drogas não foi devida a efeitos não-específicos uma vez que elas não produziram efeitos no teste do campo aberto. Os resultados sugerem que mecanismos dopaminérgicos devem estar envolvidos tanto na aquisição, quanto na expressão do medo condicionado à luz. Receptores D1 pós-sinápticos parecem participar da aquisição do congelamento condicionado à luz-CS, mas não do SPM. Por outro lado, receptores D2 pré-sinápticos parecem estar envolvidos na expressão do medo condicionado à luz-CS. / The increase in the startle reflex in the presence of a stimulus that has been previously paired to footshock is taken as an index of fear and named fear potentiated startle (FPS). Freezing behavior, a cessation of all observable movements, except those associated with respiration, has also been used as an index of fear in rats. A growing body of evidence has suggested that dopaminergic mechanisms are implicated in different aspects of affective memory, namely its formation, expression or retrieval. However, the results of studies that have examined how, and through which receptors, dopaminergic mechanisms influence fear have been inconsistent. This work is aimed at examining the involvement of dopaminergic receptors in the acquisition and expression of conditioned fear to ligth-CS. We evaluated the effects of systemic administration of the D1 antagonist, SCH 23390, the D1 agonist, SKF 38393, the D2 antagonist, sulpiride, and the D2 agonist, quinpirole before and after conditioning on FPS and freezing. The motor activity of the animals was also evaluated in an open field test. SCH 23390, SKF 38393, sulpiride and quinpirole, injected before conditioning sessions, did not produce any effect on FPS, but SCH 23390 decreased freezing. Injections of SCH 23390, SKF 38393 and sulpiride before testing session did not produce any effect on FPS or freezing. Quinpirole, injected at doses acting at presynaptic level, caused significant reduction in FPS and freezing, when injected before testing. Drugs’ action was not due to nonspecific effects since they had no effect in the open field test. Our findings indicate that DA mechanisms are involved in the acquisition and expression of conditioned fear using light-CS. Dopaminergic mechanisms mediated by postsynaptic D1 receptors seem to be involved in the acquisition of conditioned freezing to light-CS, but not in FPS. On the other hand, dopaminergic mechanisms mediated by presynaptic D2 receptors seem to be involved in the expression of conditioned fear to light-CS.

O aumento do reflexo de sobressalto na presença de um estímulo que tenha sido previamente pareado a choques nas patas é tomado como índice de medo e nomeado sobressalto potencializado pelo medo (SPM). O congelamento, interrupção de todos os movimentos observáveis, exceto aqueles associados com a respiração, também tem sido utilizado como índice de medo em ratos. Um crescente número de evidências sugere o envolvimento de mecanismos dopaminérgicos em diferentes aspectos da memória afetiva, como sua formação, evocação e expressão. No entanto, resultados sobre como e por meio de quais receptores os mecanismos dopaminérgicos influenciam o medo têm sido inconsistentes. O presente estudo examina o envolvimento dos receptores dopaminérgicos na aquisição e na expressão do medo condicionado à luz. Para isso, foram analisados os efeitos do antagonista D1, SCH 23390, do agonista D1, SKF 38393, do antagonista D2, sulpirida, e do agonista D2, quimpirole, no SPM e no congelamento. A atividade motora dos animais também foi avaliada no teste do campo aberto. SCH 23390, SKF 38393, sulpirida e quimpirole, administrados antes do condicionamento, não produziram efeitos no SPM, mas SCH 23390 diminuiu o congelamento. As administrações de SCH 23390, SKF 38393 e sulpirida antes do teste também não produziram efeitos no SPM e no congelamento. Quimpirole, em doses que agem em receptores pré-sinápticos, causou uma redução significativa no SPM e no congelamento, quando administrado antes do teste. A ação das drogas não foi devida a efeitos não-específicos uma vez que elas não produziram efeitos no teste do campo aberto. Os resultados sugerem que mecanismos dopaminérgicos devem estar envolvidos tanto na aquisição, quanto na expressão do medo condicionado à luz. Receptores D1 pós-sinápticos parecem participar da aquisição do congelamento condicionado à luz-CS, mas não do SPM. Por outro lado, receptores D2 pré-sinápticos parecem estar envolvidos na expressão do medo condicionado à luz-CS. / The increase in the startle reflex in the presence of a stimulus that has been previously paired to footshock is taken as an index of fear and named fear potentiated startle (FPS). Freezing behavior, a cessation of all observable movements, except those associated with respiration, has also been used as an index of fear in rats. A growing body of evidence has suggested that dopaminergic mechanisms are implicated in different aspects of affective memory, namely its formation, expression or retrieval. However, the results of studies that have examined how, and through which receptors, dopaminergic mechanisms influence fear have been inconsistent. This work is aimed at examining the involvement of dopaminergic receptors in the acquisition and expression of conditioned fear to ligth-CS. We evaluated the effects of systemic administration of the D1 antagonist, SCH 23390, the D1 agonist, SKF 38393, the D2 antagonist, sulpiride, and the D2 agonist, quinpirole before and after conditioning on FPS and freezing. The motor activity of the animals was also evaluated in an open field test. SCH 23390, SKF 38393, sulpiride and quinpirole, injected before conditioning sessions, did not produce any effect on FPS, but SCH 23390 decreased freezing. Injections of SCH 23390, SKF 38393 and sulpiride before testing session did not produce any effect on FPS or freezing. Quinpirole, injected at doses acting at presynaptic level, caused significant reduction in FPS and freezing, when injected before testing. Drugs’ action was not due to nonspecific effects since they had no effect in the open field test. Our findings indicate that DA mechanisms are involved in the acquisition and expression of conditioned fear using light-CS. Dopaminergic mechanisms mediated by postsynaptic D1 receptors seem to be involved in the acquisition of conditioned freezing to light-CS, but not in FPS. On the other hand, dopaminergic mechanisms mediated by presynaptic D2 receptors seem to be involved in the expression of conditioned fear to light-CS.

Long-term postnatal treatment of rats with SCH 23390 is associated with a reduction in the development of dopamine D1 receptors in the striatum. Because the tripeptide, l-prolyl-l-leucylglycinamide (PLG) attenuates the neuroleptic-induced increase in D2 receptors in the striatum in adult rats, this study was undertaken with the objective of determining whether PLG could modulate a developmental alteration in the D1 subtype of receptor. Rats were treated with the dopamine D1 receptor antagonist, SCH 23390 (R[+]-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1-H-3benzazepine) (0.30 mg/kg/d i.p.) for 32 successive days from birth, while D1 receptors in the striatum were assessed at 5 and 8 weeks from birth. Postnatal treatment with SCH 23390 reduced in vitro binding of [3H]SCH 23390 to homogenates in the striatum by 70% at 8 weeks. Scatchard analysis at 5 weeks determined that the Bmax for the binding of [3H]SCH 23390 was reduced by 78%, while the Kd was unaltered. When PLG (1.0 mg/kg/d i.p.) was administered together with SCH 23390 for the initial 32 days from birth, the binding of [3H]SCH 23390 to homogenates of the striatum was unchanged from that of the control group at 8 weeks. Also, at 5 weeks the Bmax and Kd were unaltered from control in the group that was treated with both SCH 23390 and PLG. The binding of [3H]SCH 23390 was not altered from control in the group treated with PLG alone. Also, PLG given in vitro did not alter the binding of [3H]SCH 23390 to control homogenates of the striatum. These findings indicate that PLG is able to attenuate neuroleptic-induced alterations in dopamine d1 receptors in the striatum.

The effect of chronic postnatal treatment of rats with selective D1- and/or D2-receptor antagonists on the development of D1- and D2-receptors in the striatum was studied. When neonatal rats were treated postnatally from the day of birth for 32 successive days with the D1-receptor antagonist, SCH-23390 (0.30 mg/kg i.p.), the development of striatal dopamine D1-receptors was markedly impaired, and the development of striatal D2-receptors was slightly impaired. Alternatively, chronic treatment with the D2-receptor antagonist, spiroperidol (1.0 mg/kg i.p.), resulted in a markedly impaired development of striatal dopamine D2-receptors, and a slightly impaired development of striatal D1-receptors. Scatchard analysis revealed that chronic SCH-23390 treatment during development resulted in a 78% decrease in the Bmax for in vitro binding of [3H]SCH-23390 to striatal homogenates, while the Kd was unaltered. Similarly, chronic postnatal treatment with spiroperidol was associated with a 74% reduction in the Bmax, while the Kd for in vitro binding of [3H]spiroperidol to striatal homogenates was unchanged. These findings demonstrate that chronic selective dopamine receptor antagonism affects development of both striatal D1- and D2-receptor types. The critical period during which striatal dopamine receptor ontogeny can be altered is not restricted to prenatal periods, since suitable postnatal challenge will alter striatal dopamine-receptor development.

Because the tripeptide MIF-1 (Pro-Leu-Gly-NH2) is known to attenuate the effects of neuroleptic-induced catalepsy as well as neuroleptic-induced proliferation of dopamine (DA) receptors, we studied the related naturally occurring peptide, Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2) for similar properties. Male rats were treated SC for 11 consecutive days with either the DA D1 receptor antagonist SCH 23390 HC1 (0.50 mg/kg per day), the DA D2 receptor antagonist spiperone HCl (0.30 mg/kg per day), or vehicle. Half the rats were cotreated daily with Tyr-MIF-1 (1.0 mg/kg per day). The cataleptic effects of SCH 23390 were not altered by Tyr-MIF-1. Tolerance to SCH 23390-induced catalepsy did not develop during the 11-day treatment, and Tyr-MIF-1 had no effect on SCH 23390-induced catalepsy. However, tolerance developed to spiperone-induced catalepsy, and Tyr-MIF-1 attenuated this development of tolerance (p < 0.001). Locomotor and stereotyped activities of the DA D1 and D2 agonists, SKF 39393 (3.0 mg/kg) and quinpirole (3.0 mg/kg) were not affected by Tyr-MIF-1 after treatment with the DA antagonists was discontinued. Tyr-MIF-1 did not alter the Bmax or Kd for in vitro binding of [3H]SCH 23390 and [3H]spiperone to homogenates of the striatum. These findings indicate that Tyr-MIF-1 is able to selectively affect the development of receptor tolerance to a DA D2 receptor antagonist, and that this effect is unrelated to changes in affinity or numbers of D2 receptors.

Psychological disorders such as autism, obsessive-compulsive disorder, drug addiction, and attention-deficit/hyperactivity disorder involve atypically persistent behavior and atypical activity of the neurotransmitter dopamine. Behavioral momentum theory states that the persistence of behavior in a context is determined by the reinforcement received previously in that context. Contexts previously associated with higher rates of reinforcement yield greater persistence of behavior than contexts previously associated with lower rates of reinforcement. According to a prominent hypothesis in behavioral neuroscience, dopamine mediates the incentive salience of a stimulus. A synthesis of behavioral momentum theory and the incentive salience hypothesis proposes similar roles for dopamine activity and reinforcement in determining the persistence of behavior in a context. The aim of this dissertation was to determine the extent to which a history of dopamine modulation in a context affects the subsequent persistence of behavior in extinction and relapse. Three groups of rats were trained to press a lever for food in two alternating contexts of a multiple schedule. Following a stable baseline, rats entered a treatment phase in which they received a drug or saline injection before and after sessions in each context. In the drug context, rats received the indirect dopamine agonist amphetamine, dopamine D1 antagonist SCH 23390, or a combination of amphetamine and SCH 23390 prior to the session and a saline injection following the session. The injection schedule was reversed for the saline context such that rats received a saline injection prior to each session in the saline context and a drug injection following the session. During an extinction phase, access to food was withheld. Response-independent food was then provided in each context to trigger reinstatement of responding. A history of dopamine agonism in a context increased the relative persistence of behavior, while a history of dopamine antagonism at D1 receptors and a combination of dopamine agonism and dopamine antagonism had little impact on the relative persistence of behavior. Likewise, reinstatement was relatively greater in a context previously associated with dopamine agonism. This effect was blocked when dopamine agonism was preceded by D1 antagonism. A history of D1 antagonism alone did not affect reinstatement. These results suggest that dopamine plays a role in the persistence of behavior in extinction and relapse, but that different dopamine receptors mediate these effects.

On the morning of the first day of pregnancy, Wistar rats were administered a single IP injection of either zinc sulfate (10.0 mg/kg) or saline. For the remainder of pregnancy, half the rats in each group then consumed filtered tap water while the other half consumed filtered tap water with 50 ppm of cadmium (CdCl2). At eight weeks after birth, the behavioral profile of male offspring was assessed in the following way: Apomorphine (non-selective dopamine receptor agonist), (+)-7-hydroxy-2-(di-n-propylamino) tetralin (7-OH-DPAT) (D3 agonist) and (+/-)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol (SKF 38393) (D1 agonist) were used to evaluate stereotyped behavior, yawning activity and oral movements - indices for these respective agonists. In addition, two dopamine receptor antagonists, haloperidol (D2 antagonist) and 7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzapine (SCH 23390) (D1 antagonist) were used to evaluate cataleptogenic activity. Additional behavioral parameters studied were locomotor activity, irritability and reaction to a painful stimulus. Dopamine and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and 3-methoxytyramine (3-MT) were quantified in the striatum, hippocampus and in the frontal cortex of the brain by means of HPLC/ED technique. In addition, cadmium levels were analyzed in the brain, liver, kidney and bone of newborn rats. Our results indicate that prenatal exposure of pregnant rats to cadmium produced alterations in the reactivity of central dopamine receptors and modulated the level of dopamine and its metabolites in the offsprings' brains. A single injection of zinc, preceding cadmium consumption, attenuated some of the effects of cadmium on the offsprings' dopaminergic system. Zinc also reduced cadmium deposition in the brain, kidney and bone, but enhanced its accumulation in liver. In summary, zinc may exert some neuroprotective effects against cadmium neurotoxicity.

Previous reports have indicated that prenatal, but not postnatal, haloperidol impairs the ontogenic development of striatal dopamine D-2 receptors. In the present study a specific D-2 receptor antagonist, spiroperidol (1.0 mg/kg i.p.) and/or a specific D-1 receptor antagonist, SCH 23390 (0.30 mg/kg i.p.), was administered to rats for 32 successive days from birth. Postnatal spiroperidol and SCH 23390 treaments markedly impaired the development of striatal dopamine D-2 and D-1 receptors, respectively, at 12 weeks after birth. Spiroperidol did not affect D-1 receptor development and did not modify the effect of SCH 23390 treatment. Also, SCH 23390 did not affect D-2 receptor development and did not modify the effect of spiroperidol treatment. When rats with impaired development of striatal D-2 receptors were challenged at 12 weeks with spiroperidol (1.0 mg/kg per day i.p. × 17 days) D-2 receptors did not up-regulate. However, when rats with impaired development of striatal D-1 receptors were challenged at 12 weeks with SCH 23390 (0.30 mg/kg per day i.p. × 17 days) D-1 receptors did up-regulate. These findings demonstrate that postnatal treatment with D-1 and D-2 receptor antagonists can permanently impair the development of striatal D-1 and D-2 receptors. Moreover, the ability of developmentally impaired striatal D-1 receptors to up-regulate in adulthood appears to be greater than that for the developmentally impaired striatal D-2 receptors.

Nitric acid has been implicated in a variety of physiological functions of the mammalian brain, and in a large number of its pathologies. Recently we have demonstrated that a nitric oxide donor (L-arginine) and a nitric-oxide-synthase-inhibitor (nitro-L-arginine-methyl-ester) modified the response of central al dopamine D 1 and D 3 receptors to some of their agonists. In the present study we demonstrate the modulatory effect of L-arginine, nitro-L-arginine-methyl-ester and molsidomine (another nitric oxide donor) on the reactivity of the central dopamine receptors to specific agonists and antagonists. The agonists tested were SKF-38393, 7-OH-DPAT and quinpirole, and the antagonists - SCH-23390 and haloperidol. They were evaluated in the rat by the following behavioral methods: locomotor activity, locomotor coordination, rearings and cataleptogenic activity (D 2 modulation); grooming time (D 1 activation); yawning (D 3 activation) and ethanol- and phenobarbital-sleeping-time parameters after SKF-38393 or quinpirole pretreatment. Our results suggest that nitro-L-arginine-methyl-ester is effective in modulating the reactivity of the central dopamine receptors D 2, D 1 and D 3, to their agonists and antagonists, and that it is much more effective than L-arginine in regulating the righting reflex after ethanol and phenobarbital, in both female and male mature rats.